[1]李 博.紫杉醇加顺铂治疗晚期老年非小细胞癌的疗效[J].医学信息,2020,33(10):153-154.[doi:10.3969/j.issn.1006-1959.2020.10.045]
　LI Bo.Paclitaxel Plus Cisplatin in the Treatment of Advanced Elderly Non-small Cell Carcinoma[J].Medical Information,2020,33(10):153-154.[doi:10.3969/j.issn.1006-1959.2020.10.045]
点击复制

紫杉醇加顺铂治疗晚期老年非小细胞癌的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年10期
页码:
153-154
栏目:
药物与临床
出版日期:
2020-05-15

文章信息/Info

Title:
Paclitaxel Plus Cisplatin in the Treatment of Advanced Elderly Non-small Cell Carcinoma
文章编号:
1006-1959（2020）10-0153-02
作者:
李 博
（佳木斯市中心医院肿瘤内科，黑龙江 佳木斯 154002）
Author(s):
LI Bo
(Department of Oncology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
紫杉醇; 顺铂; 晚期; 非小细胞癌
Keywords:
Paclitaxel; Cisplatin; Advanced stage; Non-small cell carcinoma
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2020.10.045
文献标志码:
A
摘要:
目的 研究紫杉醇加顺铂治疗晚期老年非小细胞癌临床疗效。方法 选取2017年3月~2018年3月在我院治疗的94例晚期老年非小细胞癌患者为研究对象，采用随机数字表法分为对照组和观察组，各47例。对照组采用顺铂治疗，观察组在对照组基础上加用紫杉醇，比较两组临床治疗总有效率、免疫功能指标（CD4、CD8、CD4/CD8）、生存率（10个月、20个月）以及毒副反应（白细胞减少、消化道反应、肝肾功能异常、血小板降低）发生情况。结果 观察组治疗总有效率为82.97%，高于对照组的72.34%（P＜0.05）；治疗后两组免疫功能指标CD4、CD8、CD4/CD8均高于治疗前，且观察组高于对照组（P＜0.05）；观察组生存率高于对照组（P＜0.05）；观察组毒副反应发生率为17.02%，与对照组的19.14%比较，差异无统计学意义（P＞0.05）。结论 紫杉醇加顺铂治疗晚期老年非小细胞癌有效率高，有助于提高患者免疫功能，促进治疗耐受性，增加患者的生存时间，且毒副反应少，具有重要的临床应用价值。
Abstract:
Objective To study the clinical efficacy of paclitaxel plus cisplatin in the treatment of advanced elderly non-small cell carcinoma. Methods 94 patients with advanced non-small cell carcinoma who were treated in our hospital from March 2017 to March 2018 were selected as the research object. They were divided into a control group and an observation group with a random number table method, each with 47 cases. The control group was treated with cisplatin. The observation group was added paclitaxel on the basis of the control group. The total clinical efficacy, immune function indexes (CD4, CD8, CD4/CD8) and survival rate (10 months, 20 months) of the two groups were compared and the occurrence of side effects (leukopenia, gastrointestinal reactions, liver and kidney dysfunction, platelet reduction).Results The total effective rate of treatment in the observation group was 82.97%, higher than 72.34% in the control group(P<0.05); after treatment, the immune function indexes CD4, CD8, CD4/CD8 of both groups were higher than before treatment, and the observation group was higher than the control group(P<0.05); the survival rate of the observation group was higher than the control group(P<0.05); the incidence of side effects in the observation group was 17.02%, and compared with 19.14% of the control group, the difference was not statistically significant (P>0.05).Conclusion Paclitaxel plus cisplatin is highly effective in the treatment of advanced non-small cell carcinoma of the elderly. It can help improve the immune function of patients, promote treatment tolerance, increase the survival time of patients, and have fewer toxic and side reactions.

参考文献/References:

[1]张晓东,陆俊国,李桃,等.重组人血管内皮抑制素和多西紫杉醇联合顺铂方案治疗晚期非小细胞肺癌的临床观察[J].临床内科杂志,2017,34(2):94-95.[2]张庆忠,刘月娟.非小细胞肺癌紫杉醇类联合顺铂同步放化疗的临床对比探讨[J].北方药学,2017,14(3):54-55.[3]钟媛,张明,兰海涛.艾迪注射液联合TP治疗老年中晚期非小细胞肺癌观察[J].现代临床医学,2017,43(2):120-121.[4]石磊,杨卫兵,拍玉举,等.顺铂联合重组人血管内皮抑素对老年恶性胸腔积液血管内皮生长因子、血基质金属蛋白酶-9表达及生活质量的影响[J].中国老年学杂志,2016,36(9):4230-4232[5]王丹丹.紫杉醇联合顺铂方案在局部晚期宫颈癌患者术前新辅助化疗中的疗效观察[J].肿瘤基础与临床,2017,30(1):52-53.

相似文献/References:

[1]刘贤丰,李子俊.恩度联合培美曲塞与顺铂治疗晚期肺腺癌的临床效果观察[J].医学信息,2019,32(03):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]
　LIU Xian-feng,LI Zi-jun.Clinical Observation of Endo Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma[J].Medical Information,2019,32(10):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]
[2]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,32(07):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
　LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Medical Information,2019,32(10):150.[doi:10.3969/j.issn.1006-1959.2019.07.046]
[3]刘 贝,郑 慧,周 旺,等.3D-STI联合心脏综合指数评价肺癌患者GP化疗方案的隐匿性心肌毒性[J].医学信息,2019,32(08):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
　LIU Bei,ZHENG Hui,ZHOU Wang,et al.Evaluation of Occult Myocardial Toxicity in GP Chemotherapy Regimen of Lung Cancer Patients by 3D-STI Combined with Cardiac Comprehensive Index[J].Medical Information,2019,32(10):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
[4]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
　ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(10):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[5]李菡旖.顺铂同步放化疗方案治疗中晚期宫颈癌的疗效[J].医学信息,2019,32(24):103.[doi:10.3969/j.issn.1006-1959.2019.24.034]
　LI Han-yi.Efficacy of Cisplatin Concurrent Chemoradiotherapy for Advanced Cervical Cancer[J].Medical Information,2019,32(10):103.[doi:10.3969/j.issn.1006-1959.2019.24.034]
[6]任勇军,闵旭立,徐 浩,等.洛铂联合表柔比星化疗栓塞治疗原发性肝细胞癌的疗效[J].医学信息,2019,32(24):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
　REN Yong-jun,MIN Xu-li,XU Hao,et al.Efficacy of Loplatin Combined with Epirubicin Chemotherapy and Embolization for Primary Hepatocellular Carcinoma[J].Medical Information,2019,32(10):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
[7]王小毛,黄 晶,石 峰.金龙胶囊对耐紫杉醇及卡铂卵巢癌H08910细胞的逆转及增敏作用[J].医学信息,2020,33(04):94.[doi:10.3969/j.issn.1006-1959.2020.04.028]
　WANG Xiao-mao,HUANG Jing,SHI Feng.Reversion and Sensitization Effect of Jinlong Capsule on Paclitaxel and Carboplatin-resistant Ovarian Cancer H08910 Cells[J].Medical Information,2020,33(10):94.[doi:10.3969/j.issn.1006-1959.2020.04.028]
[8]葛文军,宋继荣.紫杉醇联合洛铂在局部晚期宫颈癌患者术前新辅助化疗中的应用[J].医学信息,2020,33(13):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
　GE Wen-jun,SONG Ji-rong.Paclitaxel Combined with Lobaplatin in Neoadjuvant Chemotherapy for Patients with Locally Advanced Cervical Cancer[J].Medical Information,2020,33(10):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
[9]吴仁瑞,汪 琛,刘 超.紫杉醇联合卡铂方案同步放化疗在Ⅲ期胃食管结合部癌中的近期疗效和安全性[J].医学信息,2022,35(20):52.[doi:10.3969/j.issn.1006-1959.2022.20.012]
　WU Ren-rui,WANG Chen,LIU Chao.Short-term Efficacy and Safety of Concurrent Chemoradiotherapy with Paclitaxel and Carboplatin in Stage Ⅲ Gastroesophageal Junction Cancer[J].Medical Information,2022,35(10):52.[doi:10.3969/j.issn.1006-1959.2022.20.012]
[10]石少庆,宋丽丽.紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的治疗效果及对患者病理变化的影响[J].医学信息,2023,36(02):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]
　SHI Shao-qing,SONG Li-li.The Therapeutic Effect of Paclitaxel Combined with Carboplatin in Neoadjuvant Chemotherapy for Triple Negative Breast Cancer and its Effect on Pathological Changes[J].Medical Information,2023,36(10):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]

更新日期/Last Update: 2020-05-15